{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021752","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.119129+00:00","generated_at":"2026-06-15T02:37:31.334086+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Frequency reports Q1 net loss $19.5M; cash $66.7M, debt prepaid; MS program on track for 2024","bullets":["Net loss of $19.5M vs $23.4M in Q1 2022; R&D expenses $11.4M, G&A $9.2M.","Cash, equivalents and marketable securities $66.7M at March 31, 2023; all outstanding loans prepaid in April.","MS remyelination program on track for clinical start in H1 2024; novel NCEs show robust in vivo remyelination.","Preclinical data show statistical improvements in MRI white matter volume and oligodendrocyte differentiation across species.","Company exploring strategic options to create shareholder value; restructuring extends cash runway into 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021752","json":"https://secwatch.observer/filing/0000950170-23-021752.json","markdown":"https://secwatch.observer/filing/0000950170-23-021752.md","text":"https://secwatch.observer/filing/0000950170-23-021752.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000095017023021752/0000950170-23-021752-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000095017023021752/freq-20230512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:37:31.334086+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ea6e2a67bd4ff72c9d526c1a76176699a3be117c","claim":"Korro Bio, Inc. reported the quarter ended March 31, 2023 results: net income Net loss was $19.5 million.","evidence_excerpt":"On May 12, 2023, Frequency Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000095017023021752/0000950170-23-021752-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss was $19.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}